Comment on: “FGF-23 and Long-Term Outcome in Peripheral Artery Disease”

Abstract

Get full access to this article

View all access options for this article.

References

Zierfuss

Bojic

Schernthaner

Höbaus

FGF-23 and long-term outcome in peripheral artery disease. Angiology. 2026;77(5):630-636.

Valdes

Ikram

Taylor

, et al. Preoperative inflammatory biomarkers reveal renal involvement in postsurgical mortality in hip fracture patients: an exploratory study. Front Immunol. 2024;15:1374526.

Akin

Aydogan

Emre

, et al. Role of serum fibroblast growth factor-23 and Klotho level in COVID-19 infection-related mortality: a prospective study. J Infect Dev Ctries. 2024;18(12.1):S326-S330.

Courbon

David

Fibroblast growth factor 23 is pumping iron: C-terminal-fibroblast growth factor 23 cleaved peptide and its function in iron metabolism. Curr Opin Nephrol Hypertens. 2024;33(4):368-374.

Abinti

Vettoretti

Caldiroli

, et al. Associations of intact and C-terminal FGF23 with inflammatory markers in older patients affected by advanced chronic kidney disease. J Clin Med. 2024;13(13):3967.

Donate-Correa

Martín-Núñez

Hernández-Carballo

, et al. FGF23 as a potential pathophysiological factor in peripheral arterial disease associated with chronic kidney disease. Int J Mol Sci. 2024;25(10):5457.

Freise

Jernej

Metzkow

Schnorr

Taupitz

Fibroblast growth factor-23 remodels vascular extracellular matrix via glycosaminoglycan induction: implications for calcification in chronic kidney disease. Ren Fail. 2025;47(1):2567528.